TrueMark Investments LLC Grows Stock Holdings in Johnson & Johnson $JNJ

TrueMark Investments LLC grew its holdings in Johnson & Johnson (NYSE:JNJ) by 7.7% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 41,573 shares of the company’s stock after acquiring an additional 2,982 shares during the period. Johnson & Johnson comprises approximately 1.6% of TrueMark Investments LLC’s portfolio, making the stock its 19th biggest holding. TrueMark Investments LLC’s holdings in Johnson & Johnson were worth $8,604,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Capital International Investors grew its position in Johnson & Johnson by 545.6% in the third quarter. Capital International Investors now owns 3,865,050 shares of the company’s stock worth $716,657,000 after acquiring an additional 3,266,354 shares in the last quarter. Amundi raised its position in Johnson & Johnson by 19.3% during the third quarter. Amundi now owns 13,354,936 shares of the company’s stock valued at $2,512,719,000 after purchasing an additional 2,163,838 shares during the period. Marshall Wace LLP raised its position in Johnson & Johnson by 126.3% during the third quarter. Marshall Wace LLP now owns 3,584,162 shares of the company’s stock valued at $664,575,000 after purchasing an additional 2,000,609 shares during the period. Danske Bank A S bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at approximately $367,467,000. Finally, Wellington Management Group LLP boosted its holdings in shares of Johnson & Johnson by 3.8% in the 3rd quarter. Wellington Management Group LLP now owns 25,832,777 shares of the company’s stock worth $4,789,914,000 after purchasing an additional 956,239 shares during the period. 69.55% of the stock is currently owned by institutional investors.

Insider Activity

In other Johnson & Johnson news, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the completion of the transaction, the executive vice president directly owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 22,623 shares of Johnson & Johnson stock in a transaction that occurred on Wednesday, February 18th. The shares were sold at an average price of $244.33, for a total transaction of $5,527,477.59. Following the sale, the executive vice president owned 26,769 shares of the company’s stock, valued at approximately $6,540,469.77. The trade was a 45.80% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders sold 30,142 shares of company stock valued at $7,360,528. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Up 0.8%

Shares of Johnson & Johnson stock opened at $244.48 on Wednesday. Johnson & Johnson has a 12-month low of $141.50 and a 12-month high of $251.71. The firm’s 50 day simple moving average is $238.40 and its two-hundred day simple moving average is $211.86. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. The firm has a market capitalization of $588.86 billion, a price-to-earnings ratio of 22.12, a PEG ratio of 2.40 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Saturday, January 31st. The company reported $2.46 earnings per share for the quarter. The firm had revenue of $24.28 billion for the quarter. Johnson & Johnson had a net margin of 28.46% and a return on equity of 33.04%. Analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were issued a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio is currently 47.06%.

Wall Street Analyst Weigh In

Several analysts recently weighed in on JNJ shares. Freedom Capital lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a report on Friday, January 16th. UBS Group reiterated a “buy” rating on shares of Johnson & Johnson in a research report on Monday, January 5th. Royal Bank Of Canada restated an “outperform” rating and issued a $255.00 target price on shares of Johnson & Johnson in a report on Monday. Wall Street Zen downgraded shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Finally, Argus increased their price objective on shares of Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $236.91.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Royal Bank of Canada reaffirmed an “Outperform” rating and set a $255 price target on JNJ, implying roughly a mid-single-digit upside vs. the open — a clear analyst catalyst. RBC Reaffirms Outperform
• Positive Sentiment: Royalty Pharma agreed to co‑fund R&D with J&J ($500M) to advance JNJ‑4804, de‑risking and accelerating J&J’s immunology franchise and potential future revenue streams. Royalty Pharma Partnership
• Positive Sentiment: FDA approval of ICOTYDE and strong 52‑week ICONIC program durability data reinforce J&J’s immunology narrative and near‑term product commercialization upside. ICOTYDE Approval & Results
• Positive Sentiment: Multiple analyst/industry pieces reiterate J&J’s defensive, dividend‑king status and pipeline strength, which supports demand from income and risk‑averse investors amid volatility. Dividend/Defensive Coverage
• Positive Sentiment: Quant and value‑oriented writeups argue JNJ may still be attractively valued after the rally, providing buy‑the‑dip rationale for longer‑term investors. Quant Valuation Take
• Neutral Sentiment: Broader market strength — futures rallied after reports the U.S. may wind down direct military exposure in the Iran region — is a general tailwind that helped health care names including JNJ. Market/Macro News
• Negative Sentiment: Commentary highlighting J&J’s prior “free fall” and ongoing legal exposures keeps a valuation overhang for some investors, tempering upside. Cramer / Lawsuit Coverage
• Negative Sentiment: Macro risk sentiment (extreme Fear & Greed readings) remains elevated and could pressure cyclicals; defensive names can hold up but broader market drops would likely weigh on JNJ. Market Fear Index

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.